Icotinib (CAS: 610798-31-7) is a small molecule inhibitor of the epidermal growth factor receptor (EGFR). It is used for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Icotinib was first approved by the China Food and Drug Administration (CFDA) in 2011 under the brand name Conmana. This article will provide an overview of icotinib, including its chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and a conclusion on its use.
Chemical Properties The chemical name for icotinib is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine. Its molecular formula is C22H21N3O3, and it has a formula weight of 383.42 g/mol. The CAS number for this compound is 610798-31-7.
Top Ten Keywords/Synonyms
Health Benefits Icotinib is primarily used for the treatment of advanced or metastatic NSCLC with EGFR mutations. It works by inhibiting the activity of EGFR, which is a protein that plays a key role in the growth and division of cancer cells. By blocking the activity of EGFR, icotinib can help slow or stop the growth of cancer cells, leading to improved outcomes for patients with NSCLC.
Potential Effects In clinical trials, icotinib has been shown to be highly effective at improving progression-free survival and overall survival in patients with advanced or metastatic NSCLC with EGFR mutations. It has also been found to be well-tolerated, with few serious side effects reported. Additionally, icotinib has demonstrated good pharmacokinetic properties, meaning it is well-absorbed and distributed throughout the body, and is metabolized and eliminated from the body in a predictable manner.
Product Mechanism Icotinib is a selective inhibitor of EGFR tyrosine kinase activity. It works by binding to the ATP-binding site of the EGFR molecule, thereby preventing the activation of downstream signaling pathways that promote cell growth and division. By inhibiting the activity of EGFR, icotinib can help slow or stop the growth of cancer cells.
Safety Overall, icotinib has been found to be safe and well-tolerated in clinical trials. However, like all medications, it does carry some risks of side effects and adverse events. Patients taking icotinib should be monitored regularly for any signs of allergic reactions, liver dysfunction, or other serious side effects.
Side Effects Some of the most common side effects reported with icotinib include rash, diarrhea, nausea, and vomiting. These side effects are usually mild to moderate in severity and go away on their own over time. More serious side effects, such as interstitial lung disease or renal dysfunction, are rare but can occur in some patients.
Dosing Information Icotinib is typically taken orally, either with or without food. The recommended dose for patients with NSCLC is 125 mg three times daily. Patients should follow their healthcare provider's instructions carefully when taking this medication.
Conclusion Icotinib is a highly effective and well-tolerated medication used for the treatment of advanced or metastatic NSCLC with EGFR mutations. As a selective inhibitor of EGFR tyrosine kinase activity, it helps slow or stop the growth of cancer cells. While it does carry some risks of side effects and adverse events, overall, it has been found to be safe and effective in clinical trials. Patients taking icotinib should work closely with their healthcare providers to ensure proper dosing and monitoring for any potential side effects
